[HTML][HTML] Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement

S Petersenn, M Fleseriu, FF Casanueva… - Nature Reviews …, 2023 - nature.com
Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

[HTML][HTML] Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review

N Zhang, J Wang, Y Li, B Jiang - Scientific reports, 2021 - nature.com
Primary open-angle glaucoma (POAG) is a leading cause of irreversible blindness in the
world and is influenced by various sociodemographic factors. This meta-analysis aims to …

[HTML][HTML] Prevalence of primary angle closure glaucoma in the last 20 years: a meta-analysis and systematic review

N Zhang, J Wang, B Chen, Y Li, B Jiang - Frontiers in medicine, 2021 - frontiersin.org
Purpose: This meta-analysis aims to investigate the worldwide prevalence of primary angle-
closure glaucoma (PACG) and its risk factors in the last 20 years. Methods: We conducted a …

Epidemiology and management challenges in prolactinomas

L Vroonen, AF Daly, A Beckers - Neuroendocrinology, 2019 - karger.com
Clinically relevant pituitary adenomas are present in about 1 per 1,000 of the general
population and prolactinomas are by far the most common clinical subtype of pituitary …

Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis

AH Zamanipoor Najafabadi… - The Journal of …, 2020 - academic.oup.com
Context The improved remission and complication rates of current transsphenoidal surgery
warrant reappraisal of the position of surgery as a viable alternative to dopamine agonists in …

[HTML][HTML] Update in pathogenesis, diagnosis, and therapy of prolactinoma

N Fukuhara, M Nishiyama, Y Iwasaki - Cancers, 2022 - mdpi.com
Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study

B Baussart, C Villa, A Jouinot… - European Journal of …, 2021 - academic.oup.com
Objective Microprolactinomas are currently treated with dopamine agonists. Outcome
information on microprolactinoma patients treated by surgery is limited. This study reports …

Очерки эндокринной гинекологии

ВЕ Радзинский, ОА Раевская, ИА Иловайская… - 2020 - openrepository.ru
Около 70% всех гинекологических заболеваний гормонально детерминированы.
Тактика ведения таких пациенток требует от клинициста знаний основ эндокринологии …

[HTML][HTML] First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center

L Andereggen, J Frey, RH Andres, MM Luedi… - Journal of …, 2021 - Springer
Context Although consensus guidelines recommend dopamine agonists (DAs) as the first-
line approach in prolactinomas, some patients may opt instead for upfront surgery, with the …

[HTML][HTML] Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in …

LEH Bakker, MJT Verstegen, E Ghariq, BM Verbist… - Pituitary, 2022 - Springer
Purpose To report the first experience of our multidisciplinary team with functional imaging
using 11C-methionine positron emission tomography-computed tomography (11C …